Ishihara R, Suzuki Y, Tanaka S, Fukayama S, Deguchi K, Oda S, Nakane Y, Fukumoto T
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1996 Jul;49(7):715-42.
To evaluate antimicrobial activities of tosufloxacin (TFLX), minimum inhibitory concentrations (MICs) of TFLX and other drugs were determined against clinical isolates that were obtained in our laboratory from February of 1993 to January of 1994 (Period I), and from February of 1995 to January of 1996 (Period II). The results are summarized as follows: 1. Compared to MIC90's reported by others for TFLX in the 1980's, those obtained by us against beta-streptococci, Streptococcus pneumoniae, Peptostreptococcus spp., Haemophilus influenzae and Salmonella spp. were similar to, but those obtained against other bacteria were higher than those reported values. 2. Detection frequencies of resistant strains to TFLX were compared between Period I and Period II. MIC90's of TFLX against Staphylococcus spp., Morganella morganii, Providencia spp., Pseudomonas aeruginosa, beta-streptococci, S. pneumoniae and Peptostreptococcus spp. were lower in Period II than in Period I. TFLX-insensitive or -resistant H. influenzae were found among strains isolated in either of the Periods. 3. Most of the TFLX-resistant Gram-negative organisms tested were also resistant to other NQ's. 4. TFLX showed strong antimicrobial activities against penicillin-resistant S. pneumoniae.
为评估妥舒沙星(TFLX)的抗菌活性,测定了TFLX及其他药物对1993年2月至1994年1月(第一阶段)以及1995年2月至1996年1月(第二阶段)从我们实验室分离出的临床分离株的最低抑菌浓度(MIC)。结果总结如下:1. 与其他人在20世纪80年代报道的TFLX的MIC90相比,我们针对β-链球菌、肺炎链球菌、消化链球菌属、流感嗜血杆菌和沙门氏菌属所获得的MIC90与之相似,但针对其他细菌所获得的MIC90高于报道值。2. 比较了第一阶段和第二阶段对TFLX耐药菌株的检测频率。在第二阶段,TFLX对葡萄球菌属、摩根摩根菌、普罗威登斯菌属、铜绿假单胞菌、β-链球菌、肺炎链球菌和消化链球菌属的MIC90低于第一阶段。在两个阶段分离出的菌株中均发现了对TFLX不敏感或耐药的流感嗜血杆菌。3. 大多数测试的对TFLX耐药的革兰氏阴性菌也对其他喹诺酮类药物耐药。4. TFLX对耐青霉素的肺炎链球菌显示出强大的抗菌活性。